Search International and National Patent Collections

1. (WO2017155355) ANTIBODY SPECIFICALLY BINDING TO AIMP2-DX2 PROTEIN

Pub. No.:    WO/2017/155355    International Application No.:    PCT/KR2017/002631
Publication Date: Fri Sep 15 01:59:59 CEST 2017 International Filing Date: Sat Mar 11 00:59:59 CET 2017
IPC: C07K 16/18
C12N 15/63
G01N 33/574
Applicants: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
재단법인 의약바이오컨버젼스연구단
EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION
이화여자대학교 산학협력단
Inventors: KIM, Sunghoon
김성훈
SUNG, Junsik
성준식
KWON, Nam Hoon
권남훈
SHIM, Hyunbo
심현보
NGUYEN THI, Thu ha
웬티 투하
Title: ANTIBODY SPECIFICALLY BINDING TO AIMP2-DX2 PROTEIN
Abstract:
The present invention relates to an antibody specifically binding to AIMP2-DX2 protein and, more particularly, to an antibody specifically binding to AIMP2-DX2 which recognizes, as an epitope, a polypeptide comprising an amino acid sequence represented by SEQ ID.: 1, or a fragment of the antibody, a composition for diagnosing a cancer comprising the same, and a polynucleotide and recombinant expression vector encoding the antibody, a transformed cell using the same, and a method for preparing the antibody or the fragment of the antibody. Since the antibody according to the present invention does not react with a wild-type AIMP2 protein and specifically binds to an exon2-deleted AIMP2-DX2 mutant protein, the antibody can be effectively used to confirm the presence and expression level of AIMP2-DX2 protein. AIMP2-DX2 protein is associated with pathologies, such as cancer and inflammatory diseases, etc., and is particularly overexpressed in cancer diseases, such as lung cancer, breast cancer and colorectal cancer. Therefore, the present invention can be used for developing a cancer diagnostic composition which detects AIMP2-DX2 for cancer occurrence and progression and as a biomarker.